Abstract
Background Current propagation models of COVID-19 pandemic spreading appear poorly consistent with existing epidemiological data and with evidence that SARS-CoV-2 is rapidly mutating, with potential aggressive evolution of the disease.
Methods We challenged environmental versus genetic evolution models of COVID-19 spreading, over 168,089 laboratory-confirmed infection cases in Italy, Spain and Scandinavia. Landmark dates were set for each of the countries analyzed at peak diffusion rates this date, and the doubling time versus cumulative number of diagnoses was computed. Diffusion data in Germany, France and UK provided a validation dataset on 210,239 additional cases. Mutations and mutation rates of SARS-CoV-2 versus COVID-19 spreading were analyzed at nextstrain.org/ncov/europe.
Results The mean doubling time of COVID-19 was 6.63 days in northern Italy, 5.87 days in central areas, and 5.38 days in southern Italy, for shorter COVID-19 doubling time in warmer regions. Spain extended this trend, with a mean COVID-19 doubling time of 4.2 days. Slower diffusion across progressively colder regions was observed in Scandinavia, with 9.4 days COVID-19 doubling time in Sweden, 10.8 days in Finland and 12.95 days in Norway. This model was supported by the structure of SARS-CoV-2 mutation strings upon sequential diffusion across distinct geographic areas.
Conclusions Our findings indicate COVID-19 association to a sharp North/South climate gradient, with faster spreading in southern regions. Thus, warmer climate conditions may not limit SARS-CoV-2 diffusion. Very cold regions may be better spared by recurrent courses of SARS-CoV-2 infection.
Competing Interest Statement
Saverio Alberti is founder and CEO of Oncoxx Biotech
Funding Statement
funding was provided to this research by the university of Messina and Oncoxx Biotech
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical committee by the University of Messina
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
all data referred to in the manuscript are available as needed